AUG 28·SEC EDGARLow
Curran Terrie sold $956K of ARQT
Curran Terrie sold 38,200 shares of Arcutis Biotherapeutics, Inc. (ARQT) at $25.03 ($0.96M total) across 2 trades on 2026-08-27.
StockNASDAQ · US · USDHealthcare · Biotechnology
$ARQT
Arcutis Biotherapeutics, Inc.
Price · $ARQTvia TradingView
AI sentiment · 7d0 articles
No enriched coverage for $ARQT in the last 7 days.
Insider · 30dAll trades →
- Buys
- — 0 txs
- Sells
- $1.7M 10 txs
Burnett Patrick4× · $466K
10b5-1 share of filings40%
Top stories · $ARQTMore →
AUG 14·SEC EDGAR
Burnett Patrick sold $395K of ARQT
Burnett Patrick (See Remarks) sold 15,000 shares of Arcutis Biotherapeutics, Inc. (ARQT) at an average of $26.33 ($26.08–$26.52, $0.39M total) across 2 trades over 2026-08-11 to 2026-08-12.
AUG 10·investing.com
Top healthcare stocks to watch in 2026, according to Mizuho’s latest update
Mizuho updated its U.S. healthcare “Top Picks” list for 2026, citing seven companies across biotech, medical devices, and healthcare services. Highlights include Eyepoint Pharmaceuticals (Duravyu Phase 3 data expected Aug 2026), Vaxcyte (PCV Phase 3 OPUS-1 data in Q4 2026), Erasca (raised about $632.5M in an offering), and Arcutis (Zoryve guidance $480M-$495M for 2026).
ARQT sentiment & insider activity
Recent ARQT coverage spans insider activity, corporate actions and financial news.
In the last 30 days, ARQT insiders filed 10 SEC Form 4 transactions — no purchases and 10 sales ($1.7M). The most active reporter was Burnett Patrick, See Remarks, with 4 filings. 40% of those filings were made under pre-arranged Rule 10b5-1 plans.
What's driving ARQT
The insider sale modestly reduces insider ownership, potentially signaling limited confidence but the amount is small relative to market cap.
This is an insider sale disclosure, not a company fundamental update. It may slightly affect sentiment but is unlikely to change near-term valuation on its own.
The trade focus is Zoryve revenue trajectory and the early-2027 regulatory catalyst for the infant atopic dermatitis indication.
Guidance raise plus strong ZORYVE revenue growth and multiple FDA/regulatory updates increase near-term confidence in franchise momentum and pipeline timelines.
Board expansion and a new independent director appointment is unlikely to change near-term fundamentals, but can affect governance expectations and sentiment.
alphai scores every news story that mentions ARQT with an AI model for sentiment and relevance, and aggregates insider trades from Arcutis Biotherapeutics, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
News on $ARQT
Score
Curran Terrie sold $956K of ARQT
Curran Terrie sold 38,200 shares of Arcutis Biotherapeutics, Inc. (ARQT) at $25.03 ($0.96M total) across 2 trades on 2026-08-27.
1 min readBurnett Patrick sold $395K of ARQT
Burnett Patrick (See Remarks) sold 15,000 shares of Arcutis Biotherapeutics, Inc. (ARQT) at an average of $26.33 ($26.08–$26.52, $0.39M total) across 2 trades over 2026-08-11 to 2026-08-12.
1 min readTop healthcare stocks to watch in 2026, according to Mizuho’s latest update
Mizuho updated its U.S. healthcare “Top Picks” list for 2026, citing seven companies across biotech, medical devices, and healthcare services. Highlights include Eyepoint Pharmaceuticals (Duravyu Phase 3 data expected Aug 2026), Vaxcyte (PCV Phase 3 OPUS-1 data in Q4 2026), Erasca (raised about $632.5M in an offering), and Arcutis (Zoryve guidance $480M-$495M for 2026).
5 min readArcutis Biotherapeutics, Inc. (ARQT): Results of Operations and Financial Condition
Arcutis Biotherapeutics, Inc. (ARQT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Arcutis Announces Second Quarter 2026 Financial Results and Provides Business Update • Continued strong ZORYVE® (roflumilast) net product revenue growth, with Q2 revenues of $129.9 million, +59% versus Q2 of 2025, and +23% versus Q1 of 2026, driven primarily by strong demand grow
6 min readArcutis Biotherapeutics, Inc. (ARQT): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Arcutis Biotherapeutics, Inc. (ARQT) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. arqt-20260715 FALSE 0001787306 0001787306 2026-07-15 2026-07-15 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ___________________________________________ FORM 8-K ___________________________________________ CURRENT REPORT Pursuant to Section 13 or 15(d)
3 min readTop U.S. Healthcare Stocks to Watch, According to Mizuho By Investing.com
Mizuho, via Investing.com, highlighted seven U.S. healthcare stocks for growth, citing clinical catalysts and operational updates. Price targets and ratings include EYPT $36, PCVX $163, ERAS $26, ARQT $35, LNTH $115, EHC $134, and SOLV $100. Key items include EYPT Phase 3 data in Aug 2026, PCVX Phase 3 in 4Q 2026, and LNTH PDUFA mid-Aug 2026.
4 min readArcutis' ZORYVE Crème SNDA Accepted By FDA For Infants With Atopic Dermatitis
Arcutis Biotherapeutics (ARQT) said the FDA accepted its supplemental NDA for ZORYVE (roflumilast) cream 0.05% to expand use for infants with mild to moderate atopic dermatitis aged 3 to 24 months. The FDA set a PDUFA target action date of Feb. 23, 2027, supported by INTEGUMENT-INFANT Phase 2 and Phase 1 PK data. ARQT shares closed at $27.67.
3 min read
FDA Accepts Supplemental New Drug Application for Arcutis’ ZORYVE® (roflumilast) Cream 0.05% for the Treatment of Mild to Moderate Atopic Dermatitis in Infants Down to 3 Months
Arcutis Biotherapeutics (Nasdaq: ARQT) said the FDA accepted its supplemental NDA for ZORYVE (roflumilast) cream 0.05% to expand use for mild to moderate atopic dermatitis in infants aged 3 to 24 months. The FDA set a PDUFA target action date of Feb. 23, 2027. Data cited include Phase 2 INTEGUMENT-INFANT (101 infants) and Phase 1 PK (19 infants).
5 min read
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Arcutis Biotherapeutics (Nasdaq: ARQT) said it granted 61,000 restricted stock units to 9 newly hired employees under its 2022 Inducement Plan, approved by the Compensation Committee. The RSUs were granted July 1, 2026 and vest over four years (25% annually) if employment continues, per Nasdaq Rule 5635(c)(4).
2 min readArcutis Biotherapeutics, Inc. (ARQT): Submission of Matters to a Vote of Security Holders
Arcutis Biotherapeutics, Inc. (ARQT) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. arqt-20260605 FALSE 0001787306 0001787306 2026-06-05 2026-06-05 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ___________________________________________ FORM 8-K ___________________________________________ CURRENT REPORT Pursuant to Section 13 or 15(d)
2 min read